CHF 128.00
In stock
SYN-1216-M0011 mgCHF 128.00
SYN-1216-M0055 mgCHF 270.00
SYN-1216-M01010 mgCHF 412.00
SYN-1216-M05050 mgINQ
More Information
Product Details
Synonyms (R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)pyrazine-2-carbonitrile
Product Type Chemical
Formula C20H24N8O2
MW 408.5
CAS 1404095-34-6
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: CHK1 | Kinase Group: CAMK | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

CCT244747 is a novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor. CCT244747 can inhibit cellular CHK1 activity with an IC50 of 29-170nM. In multiple tumour cell models, this has the effect of significantly enhancing the cytotoxicity of several anticancer drugs (such as gemcitabine and irinotecan) and abrogating drug-induced S and G2 arrest.

Product References
  1. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors: M. Lainchbury, et al.; J. Med. Chem. 55, 10229 (2012)
  2. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs: M.I. Walton, et al.; Clin. Cancer Res. 18, 5650 (2012)
  3. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment: I. Patties, et al.; J. Exp. Clin. Cancer Res. 38, 420 (2019)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.